JP2007504166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504166A5 JP2007504166A5 JP2006524936A JP2006524936A JP2007504166A5 JP 2007504166 A5 JP2007504166 A5 JP 2007504166A5 JP 2006524936 A JP2006524936 A JP 2006524936A JP 2006524936 A JP2006524936 A JP 2006524936A JP 2007504166 A5 JP2007504166 A5 JP 2007504166A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- type
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 claims description 42
- 108090000790 Enzymes Proteins 0.000 claims description 42
- 230000002132 lysosomal effect Effects 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000007913 intrathecal administration Methods 0.000 claims description 10
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 9
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 210000004958 brain cell Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000002418 meninge Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 241000124008 Mammalia Species 0.000 claims 9
- 208000008955 Mucolipidoses Diseases 0.000 claims 6
- 230000007423 decrease Effects 0.000 claims 5
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 3
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 3
- 208000024571 Pick disease Diseases 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 102100035028 Alpha-L-iduronidase Human genes 0.000 claims 2
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 claims 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims 2
- 208000001905 GM2 Gangliosidoses Diseases 0.000 claims 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 206010058025 Hypertensive hydrocephalus Diseases 0.000 claims 2
- 206010072927 Mucolipidosis type I Diseases 0.000 claims 2
- 206010072928 Mucolipidosis type II Diseases 0.000 claims 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims 2
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 claims 2
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims 2
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 210000000576 arachnoid Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000004502 glycogen storage disease II Diseases 0.000 claims 2
- 201000008977 glycoproteinosis Diseases 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims 2
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 claims 2
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 claims 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 206010011777 Cystinosis Diseases 0.000 claims 1
- 208000011518 Danon disease Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 claims 1
- 208000033149 Farber disease Diseases 0.000 claims 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 claims 1
- 208000017462 Galactosialidosis Diseases 0.000 claims 1
- 208000009796 Gangliosidoses Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 claims 1
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 claims 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims 1
- 108700037017 Hyaluronidase Deficiency Proteins 0.000 claims 1
- 208000005503 Hyaluronidase deficiency Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 206010072929 Mucolipidosis type III Diseases 0.000 claims 1
- 208000025797 Mucopolysaccharidosis type 4A Diseases 0.000 claims 1
- 208000025923 Mucopolysaccharidosis type 4B Diseases 0.000 claims 1
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 claims 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 claims 1
- YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 claims 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 claims 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 claims 1
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 claims 1
- 208000025802 Sanfilippo syndrome type C Diseases 0.000 claims 1
- 208000025804 Sanfilippo syndrome type D Diseases 0.000 claims 1
- 208000017460 Sialidosis type 2 Diseases 0.000 claims 1
- 201000001828 Sly syndrome Diseases 0.000 claims 1
- 206010041549 Spinal cord compression Diseases 0.000 claims 1
- 208000026589 Wolman disease Diseases 0.000 claims 1
- 201000008333 alpha-mannosidosis Diseases 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 201000006486 beta-mannosidosis Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 claims 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 claims 1
- 210000002987 choroid plexus Anatomy 0.000 claims 1
- 210000003703 cisterna magna Anatomy 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 210000001951 dura mater Anatomy 0.000 claims 1
- 210000000219 ependymocyte Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000008049 fucosidosis Diseases 0.000 claims 1
- 201000006440 gangliosidosis Diseases 0.000 claims 1
- 210000004565 granule cell Anatomy 0.000 claims 1
- 102000056929 human IDUA Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 210000004705 lumbosacral region Anatomy 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 201000007769 mucolipidosis Diseases 0.000 claims 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 1
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 claims 1
- 208000000690 mucopolysaccharidosis VI Diseases 0.000 claims 1
- 208000036707 mucopolysaccharidosis type 3C Diseases 0.000 claims 1
- 208000036725 mucopolysaccharidosis type 3D Diseases 0.000 claims 1
- 208000020004 mucopolysaccharidosis type 9 Diseases 0.000 claims 1
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 claims 1
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 claims 1
- 208000012224 mucopolysaccharidosis type IIIC Diseases 0.000 claims 1
- 208000027333 mucopolysaccharidosis type IIID Diseases 0.000 claims 1
- 208000012091 mucopolysaccharidosis type IVB Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 210000003668 pericyte Anatomy 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- 210000003446 pia mater Anatomy 0.000 claims 1
- 201000010108 pycnodysostosis Diseases 0.000 claims 1
- 208000011985 sialidosis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 102000004627 Iduronidase Human genes 0.000 description 6
- 108010003381 Iduronidase Proteins 0.000 description 6
- 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 5
- 101710126837 Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 3
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 2
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FZLJPEPAYPUMMR-RTRLPJTCSA-N 2-acetamido-2-deoxy-D-glucopyranose 1-phosphate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OP(O)(O)=O FZLJPEPAYPUMMR-RTRLPJTCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000051089 Melanotransferrin Human genes 0.000 description 1
- 108700038051 Melanotransferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/651,493 US7442372B2 (en) | 2003-08-29 | 2003-08-29 | Delivery of therapeutic compounds to the brain and other tissues |
| US10/651,493 | 2003-08-29 | ||
| PCT/US2004/028135 WO2005021064A2 (en) | 2003-08-29 | 2004-08-30 | Delivery of therapeutic compounds to the brain and other tissues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504166A JP2007504166A (ja) | 2007-03-01 |
| JP2007504166A5 true JP2007504166A5 (https=) | 2012-10-18 |
| JP5819574B2 JP5819574B2 (ja) | 2015-11-24 |
Family
ID=34217412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524936A Expired - Lifetime JP5819574B2 (ja) | 2003-08-29 | 2004-08-30 | 脳およびその他の組織への治療用化合物の送達 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US7442372B2 (https=) |
| EP (1) | EP1673104B2 (https=) |
| JP (1) | JP5819574B2 (https=) |
| AU (1) | AU2004268645B2 (https=) |
| CA (1) | CA2537238C (https=) |
| CY (1) | CY1114815T1 (https=) |
| DK (1) | DK1673104T4 (https=) |
| ES (1) | ES2441612T5 (https=) |
| PL (1) | PL1673104T5 (https=) |
| PT (1) | PT1673104E (https=) |
| SI (1) | SI1673104T2 (https=) |
| WO (1) | WO2005021064A2 (https=) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6585971B1 (en) * | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| JP2008503590A (ja) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | 組成物を細胞にデリバリーするための医学用システム及び方法 |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| DK1988823T3 (en) | 2006-02-09 | 2018-12-03 | Genzyme Corp | SLOW INTRAVENTRICULAR ADMINISTRATION |
| US20080015546A1 (en) * | 2006-07-13 | 2008-01-17 | Casas Jesus W | Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures |
| US8849372B2 (en) * | 2006-11-22 | 2014-09-30 | The General Hospital Corporation | Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent |
| WO2008070769A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Intrathecal catheter |
| SI2457920T1 (en) | 2007-01-18 | 2018-02-28 | Genzyme Corporation | Oligosaccharides containing the amino acid group and their conjugates |
| WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| PL3252161T3 (pl) * | 2007-06-06 | 2022-03-07 | Genzyme Corporation | Terapia genowa dla lizosomalnych chorób spichrzeniowych |
| US8162924B2 (en) | 2007-08-17 | 2012-04-24 | The Invention Science Fund I, Llc | System, devices, and methods including actively-controllable superoxide water generating systems |
| US20090048648A1 (en) * | 2007-08-17 | 2009-02-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Self-sterilizing device |
| US8706211B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having self-cleaning surfaces |
| US8702640B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | System, devices, and methods including catheters configured to monitor and inhibit biofilm formation |
| US8460229B2 (en) | 2007-08-17 | 2013-06-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states |
| US8114346B2 (en) * | 2007-08-17 | 2012-02-14 | The Invention Science Fund I, Llc | Event-triggered ultraviolet light sterilization of surfaces |
| US8753304B2 (en) | 2007-08-17 | 2014-06-17 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter |
| US8366652B2 (en) | 2007-08-17 | 2013-02-05 | The Invention Science Fund I, Llc | Systems, devices, and methods including infection-fighting and monitoring shunts |
| US8029740B2 (en) | 2008-07-11 | 2011-10-04 | The Invention Science Fund I, Llc | Event-triggered self-sterilization of article surfaces |
| US8734718B2 (en) | 2007-08-17 | 2014-05-27 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component |
| US8647292B2 (en) | 2007-08-17 | 2014-02-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states |
| EP2192924B1 (en) * | 2007-08-20 | 2017-10-11 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| EP2219666A4 (en) * | 2007-11-15 | 2011-05-25 | Univ North Carolina | PROSTATE ACID PHOSPHATASE FOR THE TREATMENT OF PAIN |
| HRP20170698T1 (hr) | 2008-05-07 | 2017-09-22 | Biomarin Pharmaceutical Inc. | Lizosomski usmjereni peptidi i njihove uporabe |
| US20120041287A1 (en) | 2008-12-04 | 2012-02-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including implantable devices with anti-microbial properties |
| EP2384168B1 (en) | 2008-12-04 | 2014-10-08 | Searete LLC | Actively-controllable sterilizing excitation delivery implants |
| US8585627B2 (en) | 2008-12-04 | 2013-11-19 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure |
| CA3040973A1 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| EP2475376B1 (en) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| SI3998078T1 (sl) * | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| NZ605873A (en) * | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of arylsulfatase a |
| EP2588132A4 (en) * | 2010-06-25 | 2014-10-15 | Shire Human Genetic Therapies | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS |
| RS62620B1 (sr) * | 2010-06-25 | 2021-12-31 | Shire Human Genetic Therapies | Metode i kompozicije za isporuku cns akrilsulfataze a |
| SMT201600385T1 (it) * | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| NZ605874A (en) * | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of heparan n-sulfatase |
| CN103179980B (zh) * | 2010-06-25 | 2016-09-28 | 夏尔人类遗传性治疗公司 | 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物 |
| CA2805449A1 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| JP2012062312A (ja) * | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
| CN103443270B (zh) | 2011-01-20 | 2017-06-06 | 普罗塔里克斯有限公司 | 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体 |
| JP6329483B2 (ja) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． | 組換えヒトｎａｇｌｕタンパク質およびその利用 |
| US9101678B2 (en) | 2011-11-03 | 2015-08-11 | Elwha Llc | Heat-sanitization of surfaces |
| US20130121984A1 (en) * | 2011-11-07 | 2013-05-16 | Shire Human Genetic Therapies, Inc. | Biomarkers for sanfilippo syndrome and uses thereof |
| AU2012346448B2 (en) * | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| EP2793933B1 (en) * | 2011-12-23 | 2019-04-17 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
| ES2647082T3 (es) * | 2012-07-31 | 2017-12-19 | Bioasis Technologies Inc | Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas |
| WO2014022841A1 (en) * | 2012-08-03 | 2014-02-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Cyclodextrin for the treatment of lysosomal storage diseases |
| HUE039334T2 (hu) | 2012-11-27 | 2018-12-28 | Biomarin Pharm Inc | Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai |
| EA201590582A1 (ru) * | 2012-12-07 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения |
| EP2981551B1 (en) | 2013-02-20 | 2020-06-03 | Valerion Therapeutics, LLC | Methods and compositions for treatment of pompe disease |
| CN105377039A (zh) * | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| US9994641B2 (en) | 2013-12-25 | 2018-06-12 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| CA2988529A1 (en) | 2015-06-10 | 2016-12-15 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| AU2016349528A1 (en) | 2015-11-06 | 2018-05-17 | Biomarin Pharmaceutical Inc. | Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes |
| EP4275751A3 (en) | 2016-02-24 | 2023-12-27 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| IL305449B2 (en) | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous type ii diabetes |
| KR102657707B1 (ko) * | 2016-06-02 | 2024-04-15 | 에이디에스 테라퓨틱스 엘엘씨 | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 |
| RU2764919C2 (ru) | 2016-06-13 | 2022-01-24 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Оптимизированные гены и экспрессионные кассеты cln1, и их применение |
| AU2017385274B2 (en) | 2016-12-26 | 2024-02-22 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein including BDNF |
| TWI761413B (zh) | 2016-12-26 | 2022-04-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| US11723865B2 (en) | 2017-02-08 | 2023-08-15 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
| US11541005B2 (en) | 2017-02-08 | 2023-01-03 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| AU2018345303B2 (en) | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| US11730767B2 (en) | 2018-02-23 | 2023-08-22 | Regeneration Biomedical, Inc. | Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020061366A1 (en) | 2018-09-19 | 2020-03-26 | Regeneration Biomedical, Inc. | Wnt-activated adipose-derived stem cell apparatuses, methods and systems |
| EP3670652A1 (en) * | 2018-12-18 | 2020-06-24 | NEUWAY Pharma GmbH | Vlp for the treatment of a lysosomal storage disease |
| ES2933275T3 (es) * | 2018-12-18 | 2023-02-03 | Neuway Pharma Gmbh | Un sistema de suministro de fármacos novedoso y métodos para proporcionar los mismos |
| CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
| US11446084B2 (en) | 2019-07-12 | 2022-09-20 | Neuralink Corp. | Laser drilling of pia mater |
| AU2020336984B2 (en) | 2019-08-29 | 2026-04-23 | Biomarin Pharmaceutical Inc. | Methods for treating CLN2 disease in pediatric subjects |
| AU2021217816A1 (en) | 2020-02-03 | 2022-08-11 | Gt Gain Therapeutics Sa | Combination therapy for treating MPS1 |
| KR102880902B1 (ko) * | 2021-01-29 | 2025-11-03 | 현대자동차주식회사 | 셀 기반 모빌리티 생산시스템의 운영방법 |
| CA3207482A1 (en) * | 2021-02-09 | 2022-08-18 | Jill Wood | Nootropic peptides for treating lysosomal storage diseases |
| AU2022310356A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
| WO2025125542A1 (en) * | 2023-12-15 | 2025-06-19 | F. Hoffmann-La Roche Ag | Intrathecal dosage method |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
| US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
| JPS5883691A (ja) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法 |
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| CH651755A5 (en) | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
| JPS5976086A (ja) | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
| GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
| US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
| US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
| JPS60178887A (ja) | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法 |
| JPS60199889A (ja) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法 |
| US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
| DE3437944A1 (de) | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt |
| US4713454A (en) | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4937342A (en) | 1987-11-30 | 1990-06-26 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing BH4 and its derivatives |
| US6149909A (en) | 1995-06-23 | 2000-11-21 | Women's And Children's Hospital | Synthetic α-L-iduronidase and genetic sequences encoding same |
| JP2534423B2 (ja) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
| US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| DE4308739C1 (de) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
| US5945452A (en) | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
| US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| ATE218345T1 (de) | 1994-08-05 | 2002-06-15 | Suntory Ltd | Arzneimittel gegen spinocerebellare degeneration |
| US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| DE69637875D1 (de) | 1995-09-14 | 2009-04-30 | Virginia Tech Intell Prop | Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen |
| US6002067A (en) | 1996-05-20 | 1999-12-14 | The University Of British Columbia | Transgenic mouse model for iduronidase deficiency and methods of making and using same |
| US20020076782A1 (en) | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
| GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US5922713A (en) | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
| JP4306825B2 (ja) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
| CA2328518A1 (en) * | 1998-05-13 | 1999-11-18 | Harbor-Ucla | Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US6200758B1 (en) | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| EP1175210A4 (en) | 1999-03-19 | 2003-07-09 | Enos Pharmaceuticals Inc | STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| US6569661B1 (en) | 1999-11-12 | 2003-05-27 | Biomarin Pharmaceutical Inc. | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| EP1955703A1 (en) * | 1999-11-12 | 2008-08-13 | Oncolytics Biotech Inc. | Viruses for the treatment of cellular proliferative disorders |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US6585971B1 (en) | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
| AU1775901A (en) | 1999-11-17 | 2001-05-30 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| US6972124B2 (en) * | 2000-05-01 | 2005-12-06 | Biomarin Pharmaceuticals Inc. | Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| US6544994B2 (en) | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
| WO2001097829A2 (en) * | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| AU7194101A (en) | 2000-07-18 | 2002-01-30 | Univ Duke | Treatment of glycogen storage disease type ii |
| US20050119270A1 (en) | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
| KR100916163B1 (ko) | 2000-08-31 | 2009-09-08 | 아스비오파마 가부시키가이샤 | 비오프테린류의 제조방법 |
| ATE384736T1 (de) * | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| AU2002317700A1 (en) † | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
| US20030007961A1 (en) | 2001-06-22 | 2003-01-09 | Wilburn Michael D. | Orthomolecular vitamin E derivatives |
| US20030072761A1 (en) † | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2003224880A1 (en) | 2002-04-05 | 2003-10-27 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| US20030198620A1 (en) | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
| EP1503788B1 (en) | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| DE10260263A1 (de) | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
| EP1613264A4 (en) | 2003-04-16 | 2007-08-15 | Yeda Res & Dev | MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| CA2525236C (en) * | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2006055511A2 (en) | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
-
2003
- 2003-08-29 US US10/651,493 patent/US7442372B2/en not_active Expired - Lifetime
-
2004
- 2004-08-30 CA CA2537238A patent/CA2537238C/en not_active Expired - Lifetime
- 2004-08-30 US US11/630,446 patent/US9044473B2/en active Active
- 2004-08-30 ES ES04782579T patent/ES2441612T5/es not_active Expired - Lifetime
- 2004-08-30 WO PCT/US2004/028135 patent/WO2005021064A2/en not_active Ceased
- 2004-08-30 AU AU2004268645A patent/AU2004268645B2/en not_active Expired
- 2004-08-30 PT PT47825799T patent/PT1673104E/pt unknown
- 2004-08-30 EP EP04782579.9A patent/EP1673104B2/en not_active Expired - Lifetime
- 2004-08-30 JP JP2006524936A patent/JP5819574B2/ja not_active Expired - Lifetime
- 2004-08-30 DK DK04782579.9T patent/DK1673104T4/da active
- 2004-08-30 SI SI200432119T patent/SI1673104T2/sl unknown
- 2004-08-30 PL PL04782579.9T patent/PL1673104T5/pl unknown
-
2012
- 2012-02-17 US US13/399,787 patent/US9089566B2/en not_active Expired - Lifetime
-
2014
- 2014-01-09 CY CY20141100019T patent/CY1114815T1/el unknown
-
2015
- 2015-02-05 US US14/615,098 patent/US9572870B2/en not_active Expired - Fee Related
-
2017
- 2017-01-06 US US15/400,289 patent/US11040088B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504166A5 (https=) | ||
| US12409210B2 (en) | CNS delivery of therapeutic agents | |
| Ellison et al. | Advances in therapies for neurological lysosomal storage disorders | |
| US10898551B2 (en) | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof | |
| Chen et al. | Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future | |
| JP2013534526A5 (https=) | ||
| EP1981546B1 (en) | Enzyme replacement therapy for treating lysosomal storage diseases | |
| JP5819574B2 (ja) | 脳およびその他の組織への治療用化合物の送達 | |
| Kakkis et al. | Enzyme replacement therapy in feline mucopolysaccharidosis I | |
| JP2016037504A5 (https=) | ||
| Ortolano et al. | Treatment of lysosomal storage diseases: recent patents and future strategies | |
| CA2803166A1 (en) | Cns delivery of therapeutic agents | |
| JP2015524662A5 (https=) | ||
| Abasolo et al. | Nanotechnology‐based approaches for treating lysosomal storage disorders, a focus on Fabry disease | |
| Safary et al. | Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis | |
| US10138474B2 (en) | Scavenger receptor uptake for fabry disease enzyme replacement therapy | |
| US20180326021A1 (en) | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | |
| WO2017049161A1 (en) | ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER | |
| Matzner | Therapy of lysosomal storage diseases | |
| WO2019145500A1 (en) | Method of treatment | |
| Zia et al. | Therapy for neuropathic lysosomal storage diseases | |
| HK40059834A (en) | Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally | |
| HK40126595A (zh) | 用於预防和治疗患有黏多糖贮积症ii型的受试者的溶酶体酶缺乏的药物组合物和方法 | |
| HK1230954B (en) | Cns delivery of therapeutic agents | |
| HK1230954A1 (en) | Cns delivery of therapeutic agents |